3000+ Attendees, 450 Speakers, 12 Conference Tracks, 100+ Posters
 
MMTC15_Header  
MMTC M Header 
Archived Content

De Risking Drug Discovery 

Day 1 | Day 2 | Day 3 | Download Brochure 

Wednesday, February 22

 

NETWORK PHARMACOLOGY

7:55 am Chairperson's Remarks

Jake Chen, Ph.D., Associate Professor, Informatics, Indiana University

8:00 Network Polypharmacology in Systems Lead Finding

Jeremy Jenkins, Ph.D., Senior Investigator I, DMP, Quantitative Biology, Chemical Biology Informatics, Novartis Institutes for BioMedical Research

Protein interactomics data provides the basis for network maps that can represent theoretical targets in phenotypic assays. Protein interaction networks as an organizing principle for discovering chemical leads - both alone and in combination - will be presented.

8:30 Translating Systems Biology to Systems Pharmacology: Integrating in vitro Systems Biology and Disease-PKPD Modeling to Advance the Discovery of Antibody Therapeutics

John Burke, Ph.D., Senior Principal Scientist, Head, Systems Biology and Pre-Clinical PKPD Modeling, Translational Research, Boehriniger Ingelheim Pharmaceuticals

First principals Systems Biology modeling and analysis elucidated seemingly contradictory in vitro data via model prediction. The model was then translated into the mechanistic disease-PKPD Systems Pharmacology paradigm to predict optimal therapeutic parameters. As a result, the lead was identified.

9:00 Computational Approaches in Studying Network Pharmacology

Philip E. Bourne PhD, Professor, Pharmacology, University of California, San Diego, Associate Director, RCSB Protein Data Bank, Co-founder & Editor in Chief PLoS Computational Biology

Recent success in using computational network pharmacology to explain unusual outcomes, both positive and negative, that are seen experimentally and/or clinically. Examples will be given, including Nelfinavir. Our approach combines cheminformatics, structural bioinformatics and systems biology.

KEYNOTE PRESENTATION

Sponsored by
e-Therapeutics 

9:30 De-Risking Drug Discovery Using Network
Pharmacology

Malcolm Young, Ph.D., CEO, e-Therapeutics

Statistical analysis of current attrition rates shows that preclinical and early clinical stage data do not predict efficacy, safety and deliverability in human patients nearly well enough. Further, and more accurate, ways to de-risk candidates before expensive clinical trials are urgently required.

10:00 Transition to Plenary Keynote

 

Plenary Keynote 

10:10 Plenary Keynote Presentation  

Sponsored by
Hologic Molecular Diagnostics - small logo 

11:00 Refreshment Break in the Exhibit Hall with Poster Viewing

12:00 pm Modeling Drug Efficacy Using Network Pharmacology

Jake Chen, Ph.D., Associate Professor, Informatics, Indiana University

This will describe how the study of drugs, molecules, and drug-target can benefit predictive modeling of drug effects and evaluations of their efficacy. This opens up new opportunities for future drug development; this new exciting field can revolutionize future drug development.

12:30 EXPERT PANEL: Implementing Network Pharmacology in Current Pharma Strategies: Unveiling & Championing Existing Resources

Moderator:

Jeremy Jenkins, Ph.D., Senior Investigator I, DMP, Quantitative Biology, Chemical Biology Informatics, Novartis Institutes for BioMedical Research

Panelists:

John Burke, Ph.D., Senior Principal Scientist, Head, Systems Biology and Pre-Clinical PKPD Modeling, Translational Research, Boehriniger Ingelheim Pharmaceuticals

Jake Chen, Ph.D., Associate Professor, Informatics, Indiana University

Malcolm Young, Ph.D., CEO, e-Therapeutics

Philip E. Bourne Ph.D, Professor, Pharmacology, University of California, San Diego, Associate Director, RCSB Protein Data Bank, Co-Founder & Editor in Chief PLoS Computational Biology

1:00 Luncheon Presentations (Sponsorship Opportunities Available) or Lunch on Your Own

2:00 Ice Cream Refreshment Break in the Exhibit Hall with Poster Viewing

 

Plenary Keynote Panel 

2:30 Plenary Keynote Panel  

3:50 Refreshment Break & Poster Awards in the Exhibit Hall

4:25 Organizer's Remarks

Kate Skaare, Cambridge Healthtech Institute

4:30 PANEL DISCUSSION: Creating Safety Endpoints as a Milestone within Pharmaceutical Discovery & Development

Moderator: Ernie Bush, Ph.D., Vice President, Collaborative Projects, The Drug Safety Executive Council

Panelists: Dave Watson, Eli Lilly; Michael Forstner, F.Hoffman La Roche, Thomas Schroeter, Pfizer

  • Establishing safety assessment endpoints throughout the pipeline
  • Why "one fits all" does not work
  • Pre-clinical vs. clinical endpoints

KEYNOTE PRESENTATION

5:30 Target Validation of B-Lymphocyte Stimulator and Development of Belimumab—A Case Study

William W. Freimuth, M.D., Ph.D., Vice-President of Clinical Research Immunology, Rheumatology and Infectious Diseases, Human Genome Sciences, Inc.

B-Lymphocyte Stimulator (BLyS) is a member of the TNF ligand super family responsible for the survival of antibody producing B-cells. Its experimental overexpression is associated with an autoimmune phenotype, and its increase in the blood of patients with systemic lupus erythematosus (SLE).

6:30 Close of Day



Day 1 | Day 2 | Day 3 | Download Brochure 

 



Premier Sponsors:

Leica Biosystems 
 

 NanoString2   

 

Singulex 

 

Jackson Laboratory - small logo